Last reviewed · How we verify
NCT04637321
The Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
trial testing Solid organ transplant in Infection in Solid Organ Transplant Recipients in 585 participants. Completed in 7 August 2020.
7 August 2020
Quick facts
| Lead sponsor | Methodist Health System |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 585 |
| Start date | 4 November 2019 |
| Primary completion | 7 August 2020 |
| Estimated completion | 7 August 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Solid organ transplant
Conditions studied
- Infection in Solid Organ Transplant Recipients — all drugs for Infection in Solid Organ Transplant Recipients →
Sponsor
Methodist Health System — full company profile →
Who can join
18 and older, any sex, with Infection in Solid Organ Transplant Recipients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
2.1. Study Objectives * Primary Objective(s) * Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant * Secondary Objective(s) * Identify the risk factors for recurrent CDI post-transplant in patients who were diagnosed with a CDI within one year prior to Solid Organ Transplant * Evaluate the impact of CDI on graft survival following Solid Organ Transplant
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04637321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infection in Solid Organ Transplant Recipients
Currently open trials in the same condition.
- NCT05626530 — Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients · Phase 4 · recruiting
- NCT01527591 — Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT) · NA · active not recruiting
Other Methodist Health System trials
Trials by the same sponsor.
- NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
- NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
- NCT07492758 — Management of Extremity Injuries Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04637321 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
- Last refreshed: 4 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04637321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing